Get started

Healthstocks

ABBVIE broke below the 1D MA50. Confirmed sell opportunity.AbbVie Inc. (ABBV) has been trading within a Channel Up pattern since the November 09 2023 Low. Having made a Higher High on September 04 and been rejected at the top of the Channel Up, the price broke and closed aggressively below its 1D MA50 (blue trend-line) three days ago. That is a confirmed technical sell signal. The 1D RSI has been on Lower Highs before the actual High, very similar to the previous top on March 12 2024. That sequence, after breaking below its 1D MA50, extended aggressively towards the 1D MA200 (orange trend-line) and bottomed on the 0.618 Fibonacci retracement level. As a result, we can take a low risk sell now and target a potential contact with the 1D MA200 at $180.00. As far as buying the dip for the long-term is concerned, the most consistent buy signal has been the 1D RSI Bullish Divergence when it forms the first Higher Lows sequence after breaking below the 30.00 oversold barrier. So far that has worked 3 times almost perfectly, with the only exception the May 29 2024 bottom, which still was formed not that far away from the April 26 buy signal. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVShort
by TradingShot
2
JOHNSON & JOHNSON Excellent confirmed sell signalJohnson & Johnson (JNJ) gave us the most optimal buy entry on our last call (April 17, see chart below) and easily hit our 157.50 Target: Having been rejected early in September exactly at the top (Lower Highs trend-line) of the 2-year Channel Down and now establishing price action below its 1D MA50 (blue trend-line), this is a confirmed sell signal and the start of the Channel's 5th Bearish Leg. The RSI Lower Highs are common on all previous Channel tops. Our Target is 141.00, which is on the Internal Lower Lows trend-line (formed by the last 2 Lower Lows) and still above the 1.236 Fibonacci extension. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry. Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended. The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
UNITED HEALTH forming a bottom.United Health (UNH) gave an excellent dip buy opportunity last time (March 29, see chart below), with the price even breaking above the long-term Resistance Zone eventually: The price has since entered a Channel Up pattern with the price now below its 1D MA50 (blue trend-line), having already topped and attempting to form a new Higher Low at the bottom of the pattern. Like the previous one in June, this bottoming process can take another 3 weeks, so we will time it accordingly and target 675.00 (+21.00% rise, similar to both previous Bullish Legs). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:UNHLong
by TradingShot
ELI LILLY Hit the top of the 4-year Channel. Relief sell-off?Earlier this year we gave a strong buy signal on Eli Lilly and Company (LLY) on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern: The price has now hit (last week) the top of the 4 year logarithmic Channel Up, highly overbought with the RSI on the 1W time-frame reaching 84.30, breaking above the August 16 2021 High. As last week's 1W candle closed in red (the first after 5 straight bullish weeks) this is considered so far a Higher Highs rejection and calls for an early sell signals towards the end of October, targeting the 1D MA100 (red trend-line) at $500.00, where the stock will start turning into a buy opportunity again (assuming the RSI is below 55.00). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYShort
by TradingShot
CVAC - Trade Opportunity Looking through charts, CVAC caught my eye for some potential trade opportunities. Firstly lets look at the candle close of Today 08/01/23 -> We are currently testing this RED Resistance Arrow Line pointing down -> The candle has a lower wick, indicating some buying pressure ->However, the candle body is small, which may indicate waning momentum **If price action CONFIRMS above RED ARROW -> This can be a TRADE SETUP -> If this plays out - TARGET = $10.65 or a potential 17% move -> STOP LOSS should be placed below RED ARROW Notice the GREEN circle indicating a bounce UP from 2 converging support lines -> The 200 DMA -> this is important as if we maintain support on 200 DMA, it indicates Bullish activity, price has a possibility of traveling back to UPPER BLACK RESISTANCE LINE BUT NOTE: This is the first time for CVAC to be doing this, so we have to be cautious, as FAKEOUTS are possible. -> The orange sloping support line ~~ Having 2 support lines converge makes SUPPORT two-folds stronger, which may create ncessary momentum for price to break above RED ARROW Now Notice how the ORANGE SUPPORT LINE coincides with the ORANGE line found on the RSI and MACD -> This is known as a BEARISH DIVEGENCE -> Where price shows a higher low but Indicators show lower lowers. -> This leads to PRICE DECLINES if it plays out, may lead Price Action to go towards the BLACK Support line or where the RED ARROW is pointing at. -> Its also not necessary that it plays out right away, we can technically hit my TARGET of $10.65 and then have the DIVERGENCE play out. *** Regardless of what happens, BLACK SLOPING SUPPORT LINE can be a BUY ZONE with STOP LOSS BELOW this line. This would be to catch a bounce off this line. RSI orange line MUST stay above or act as SUPPORT on the BLACK moving average, this normally leads to PRICE increasing MACD (Momentum indicator) -> must continue this histogram pattern of waning bearish momentum, we must print GREEN histogram. -> There needs to be a BULLISH CROSS where BLUE line crosses above the ORANGE line. -> This would help us breakout of the RED ARROW RESISTANCE STOCH RSI -> BLUE line has CROSSED over ORANGE, and we are ABOVE the 20 level. This indicates BULLISH MOMENTUM. -> We must continue UPWARD above the 80 level, this indicates continuation of MOMENTUM, if we keep this direction -> It may HELP us BREAKOUT of RED ARROW RESISTANCE LINE. CONCLUSION: All in all, we are in a interesting area for CVAC the stock. New things are happening in the price action, that has not been seen in the history of CVAC. 200 DMA acting as support for the 1st time, STOCH RSI Bullish cross and waning of bearish momentum in MACD can be the necessary catalyst to push PRICE above the RED ARROW RESISTANCE. If so TARGET = $10.65 or a 17% Trade. However, it is important to note the BEARISH DIVERGENCE forming, though a sign of DOWNWARD PRICE ACTION, can also lead to opportunity of a trade setup. Never fight the trend, its always better to ride along. Thanks you! Hope this helps, please support my ideas by boosting, following and commenting! Do check out my page of other trade ideas. I have linked a couple of recent ideas ive had, check em out if you'd like. DISCLAIMER: This is not Financial advice, i am NOT a Financial advisor. Thoughts expressed here are my only my opinion and for educational purposes. Do practice due diligence and focus on risk mamangement. Deploy stop losses to protect yourself. Thanks.
NASDAQ:CVAC
by SafofAllTrades
TDOC - Update after a Bullish WeekIve been eyeing TDOC for some time, finally posting a chart on it talking about TA developments that may indicate a potential bottom area earlier this week (Check below for the link to that chart). I was also in the camp of TDOC going lower to the low $20 or high Teens ($18-19). This weeks move of 30%, closing the weekly candle at 20% gains was a wonderful surprise. Its important to NOTE, however that the move is NOT SET IN STONE yet -> For WEEKLY Timeframe We are hitting a MAJOR confluence of RESISTANCES. Though we are ever so peaking our head out atm, next 1-2 weeks will show more evidence with confirmation. FOr example: Next week CLOSE being a bullish single candle or next couple weeks printing a bullish candlestick pattern sequence. The other side is that It could very well be a fake out/ SELL OFF and we do come back down to make a final lower low before we really become bullish. But in my opinion, the probability of a fake out maybe less. We've moved above the 21 week EMA as well, we would need to confirm support above it in the coming weeks but being above 21 EMA indicates bullish activity. NOTICE the Bollinger bands. Notice how it has narrowed, this could indicate volitility to pick up and we need to see price stay above median line and be near the upper band. We must Observe what happens in the coming weeks. The Bollinger median line and 21 EMA are converging and can act as strong support zone. If we do come back down in price. On the DAILY timeframe, we acted as SUPPORT on both the PURPLE major RESISTANCE line from all time highs and RESISTANCE line from July 2022. Just note however i would need more confirmation in the coming days by staying above as support, to be confident we stay at these levels. If we do, next weeks candle stays above and no fakeout occurs. RSI is breaking out of the Horizontal resistance line that kept RSI range bound since OCT 2021. (indicated by black line) This tells me, the BULLISH DIVERGENCE is at play. We would want RSI to continue UP, or follow the Green arrowed path drawn. We absolutely do NOT want the Red arrow. Which is a possibility but less probable in my opinion. STOCH RSI, a momentum indicator shows that we have a bullish momentum cross, showing that there is still gas left in the tank for us to move. Expect it to go above the 80 level. Conclusion + trade setups: For stocks that are 80+% off there tops, averaging in always is a nice strategy. I think under $30 is cheap for TDOC, especially with all these TA challenges being slowly conquered. There is no denying that it is highly probable we go up eventually, as we've reached critical historical support, and have been consolidating around here for awhile. Alot of indicators and other signs are leaning towards a bottom being formed or already formed. *CHECK OUT A more detailed TDOC chart from earlier this week BELOW* A swing trade idea could be taking positions using the Daily timeframe, putting stop loss below the PURPLE line. Making sure you manage your risk properly. I would rely more on the WEEKLY timeframe and a confirmation that we've made it above the resistance, plus weekly candles are more macro and powerful. This would also be for holding/ longer term investing. THANK YOU! Hope this update helped. If you like the content, please boost and follow. Please do comment with your opinions! Would love a discussion. DISCLAIMER: I am not a Financial advisor. This is NOT financial advise. This is my opinion and for educational purposes.
NYSE:TDOC
by SafofAllTrades
ABBV Long-term buy confirmedAbbVie Inc. (ABBV) opened today much higher than the 1D MA200 (orange trend-line), which is a strong enough buy signal on its own. Coupled however with the fact that the rebound was achieved on the Higher Lows trend-line that started way back on the COVID (March 23 2020) market bottom, it makes it an even stronger one. In fact on a 2-3 month basis, this is the most optimal buy signal an investor can have. As you see on this 1D chart, the stock had 4 Higher High touches during that period and the only time the price broke above the Channel Up was on February 16 2022 the break-out of which peaked on April 08 2022. With the help of the Fibonacci Channel levels we can see why the price stopped where it stopped. In fact we also see the important role of the median (Fib 0.5). Based on the above, we expect a new Higher high around the $180.00 price mark. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVLong
by TradingShot
1
UnitedHealthGroup Analysis 19.11.2022Welcome to the BasicTrading channel. My name is Philip and in todays analysis I quickly go over the situation which we currently have on UnitedHealth Group. I will analyse the asset both from a weekly and daily timeframe to show you the best possible trading opportunities. If you enjoyed this analysis, let me know in the comment section which asset I should analyse tomorrow. I will personally reply to every single comment. Dont forget to smash that rocket and I will see you tomorrow with a new analysis.
NYSE:UNH
by basictradingtv
3
HCAT LongTechnical Analysis : We broke the downtrend line and had three white soldiers to confirm the reversal of the trend, also the falling wedge shows a bullish reversal since we broke it upwards. Although on a lower timeframe MACD and RSI look bearish, we expect the price to reach our Buy Zone before the impulsive move upwards. Aroon : Aroon Up on Top and Aroon Down on bottom show a bullish momentum. MACD : We had lower lows on the chart but not on MACD which shows MACD divergence and signals for a reverse of the downtrend. Entry : 21.5-23.5 Target : 39.75 (at Fib50% and just below a previous high and resistance ) Invalidation : 19.5 ( Just Below our support and last low )
NASDAQ:HCATLong
by vf_investment
$CHEK Receives FDA IDE Approval for Pivotal Study of C-Scan®Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan. Now with IDE in hand, we aim to enter the last phase of demonstrating the clinical potential of C-Scan in the U.S., with the ultimate goal of commercialization in this important market. "We are in active discussions with a number of clinical sites as part of our preparations to begin the pivotal study in late 2021. finance.yahoo.com
NASDAQ:CHEK
by AlenCiken
Exela Technologies Wins $90 Million ContractExela Technologies Wins $90 Million Contract for Cloud-Hosted PCH Global, Delivering Healthcare Solutions for Major US Insurer $XELA today announced a 10 year, $90 million venture blending automation technologies, SaaS, and services through its PCH Global platform, which officially launched in September of last year. This effort will accelerate the digital transformation efforts for a major US health insurance company and is part of a broader relationship that included over $28 million in revenue in 2020. finance.yahoo.com
X
by AlenCiken
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma. Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch. The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019. H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.” “We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.” To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy. finance.yahoo.com
AMEX:ZOM
by AlenCiken
Day Traders Lighting Up Reddit Spur Rally in ZomedicaDay Traders Lighting Up Reddit Spur Rally in Tiny Health Stock Zomedica Such outsized moves in small-caps are becoming par for the course these days. Surging at the open on the back of mentions in Reddit forums was Zomedica Corp., a company that develops medicines for pets. The stock jumped as much as 98% on Monday and is up almost four-fold from the start or the year. The penny stock garnered a mention in several Reddit forums over the past few days finance.yahoo.com
AMEX:ZOM
by AlenCiken
2
$GRST - UPDATED ANALYSIS$GRST: AFTER A SUCCESSFUL BREAKOUT FROM THE CUP AND HANDLE FORMATION ABOVE .003/.0042, $GRST REACHED HIGHS NEARING THE PSYCHOLOGICAL LEVEL OF .01, AND LEVELED OFF TO RETEST THE UPTREND AND FOUND SOLID SUPPORT AT THE BREAKOUT LEVELS FROM THE PREVIOUS FORMATION. WE ARE NOW SWINGING BACK TO RETEST THE PENNY LEVEL, AND WHEN BROKEN THIS TIME AROUND WE SHOULD SEE A PARABOLIC MOVE TOWARDS .03, MANY NEW DEVELOPMENTS INCLUDING $GRST GOING CURRENT ON OTC MARKETS, ARIA FACILITY RECEIVING ITS LICENSE AND OPENING ITS DOORS TO PATIENTS. MUCH MORE MARKETING IS COMING FROM THE COMPANY TO PROMOTE THE FACILITY AND BEGIN GENERATING REVENUES.
OTC:GRSTLong
by ilovestocks85
Novartis: Buy opportunity with split entry.NVS was among the high cap losers yesterday on the renewed coronavirus tensions and pulled back dramatically (-6.90%). This however can be the buy opportunity of the next several months as it hit the 1D MA200 (orange line) and is approaching the Higher Low trend line of the 1W Channel Up (RSI = 45.378, MACD = 1.640, ADX = 65.865). Even though the MACD indicated the possibility of a deeper pull to the 84.00 1W Support before a meaningful rebound, we give equal probabilities for the rebound to start within the Higher Low zone. Our Target zone is 98.00 - 100.00. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NYSE:NVSLong
by InvestingScope